Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631 1633
This examiner grants 67% of resolved cases
Gina Pronzati works in Tech Center 1600 and Art Unit 1631, with 39 resolved cases. Her allowance rate is 66.7%, and the median days to allowance is 1284. These figures indicate that a majority of applications reach a grant, typically within this timeline. Practitioners should use the 1284-day median as a benchmark for the 39 cases in this examiner's history.
The profile also highlights an interview lift of 45.9%. This substantial lift suggests that applications involving an interview have a much higher chance of success than the 66.7% baseline. With 39 resolved cases as the basis for this data, the 45.9% lift is a strong indicator of the value of direct communication. In Art Unit 1631, practitioners should prioritize interviews to improve their odds and potentially navigate the 1284-day median pendency more effectively.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18774971 | METHODS OF PRODUCING THREE-DIMENSIONAL CELLULAR TISSUES | Non-Final OA | TOPPAN HOLDINGS INC. |
| 18600769 | METHODS AND SYSTEMS FOR EXTENDED CULTURE OF HUMAN BLASTOIDS TO POST-IMPLANTATION STAGES ON 3D MATRICES | Non-Final OA | WASHINGTON UNIVERSITY |
| 17984720 | METHODS, COMPOSITIONS, AND KITS FOR EXPANDING NATURAL KILLER CELLS | Non-Final OA | Regents of the University of Minnesota |
| 18580093 | AUF1 COMBINATION THERAPIES FOR TREATMENT OF MUSCLE DEGENERATIVE DISEASE | Non-Final OA | NEW YORK UNIVERSITY |
| 18683101 | SLC13A5 GENE THERAPY VECTORS AND USES THEREOF | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18703908 | DEDIFFERENTIATED PLANT CELLS OF THE GENUS PAEONIA, EXTRACTS THEREOF AND COSMETIC USES THEREOF | Non-Final OA | L'OREAL |
| 18701723 | COMPOSITION AND METHODS FOR RECOMBINANT LENTIVIRAL PRODUCTION | Non-Final OA | AMGEN INC. |
| 18379740 | PROLYL HYDROXYLASE DOMAIN INHIBITOR TREATMENT TO IMPROVE SURVIVABILITY OF HEMORRHAGIC SHOCK | Non-Final OA | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY |
| 17778250 | METHOD FOR FREEZING NEURAL CELLS | Non-Final OA | Kyoto University |
| 18287791 | SMAD2 INHIBITION IN BETA CELLS FOR TYPE 2 DIABETES THERAPY | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 17681538 | ADENOVIRAL ASSEMBLY METHOD | Final Rejection | Salk Institute for Biological Studies |
| 18265544 | COMPOUNDS AND METHODS TO TREAT CYSTIC FIBROSIS | Non-Final OA | City of Hope |
| 18227775 | ON DEMAND EXPRESSION OF EXOGENOUS FACTORS IN LYMPHOCYTES | Final Rejection | American Gene Technologies International Inc. |
| 17908509 | ON DEMAND EXPRESSION OF EXOGENOUS FACTORS IN LYMPHOCYTES TO TREAT HIV | Final Rejection | American Gene Technologies International Inc. |
| 17788679 | REGULATORY NUCLEIC ACID SEQUENCES | Non-Final OA | ASKLEPIOS BIOPHARMACEUTICAL, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy